ClinicalTrials.gg
RecruitingNCT07339423AMAZE 1Updated Sep 24, 2026

AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight

A Phase 3 interventional study of NNC0487-0111 and Placebo (matched to NNC0487-0111) in Obesity, sponsored by Novo Nordisk A/S. Recruiting at 72 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-24.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing zenagamtide in Obesity — 17 open to participants now, 20 under way, 14 of them phase 3. zenagamtide · Obesity.

Planned enrollment
3rd of 24
1,150 · median 360
Started
2026
with 18 others
Phase 3
14 of 24
11 open now
Primary completion
2029-06
later than 17 of 19 live
Registered
5th of 24
by date
Lead sponsor
24 of 24
Novo Nordisk A/S

Among the 24 studies testing zenagamtide in Obesity, this one is the 3rd largest by planned enrollment, is one of 19 that started in 2026, is one of 14 in phase 3, reaches primary completion later than 17 of the 19 other live ones, and was the 5th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

17 of the 24 studies testing zenagamtide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About zenagamtide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing zenagamtide in Obesity, or all of them as a file.
02

Study summary

The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.

03

Conditions studied

  • Obesity

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male or female (sex at birth).
  • obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
  • History of at least one self-reported unsuccessful dietary effort to lose body weight.

Key Exclusion Criteria:

  • ≥ 6.5% (48 millimole per mole [mmol/mol]) as measured by the central laboratory at screening.
  • History of type 1 or type 2 diabetes mellitus as declared by the participant or reported in the medical records.
  • Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues before screening.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,150 participants (estimated)

Study arms

  • Experimental
    NNC0487-0111

    Participants will be randomized to receive 1 out of 4 different dose levels subcutaneously once weekly as an adjunct to a reduced-calorie diet and increased physical activity.

    Drug: NNC0487-0111

  • Placebo comparator
    Placebo

    Participants will receive placebo matched to NNC0487-0111 subcutaneously once weekly as an adjunct to a reduced-calorie diet and increased physical activity.

    Drug: Placebo (matched to NNC0487-0111)

Interventions

  • NNC0487-0111 will be administered subcutaneously using PDS290 pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.

  • DrugPlacebo (matched to NNC0487-0111)

    Placebo matched to NNC0487-0111 will be administered subcutaneously using PDS290 pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.

06

What researchers measure

Primary outcomes

  1. Relative change in body weight

    Measured as percentage of body weight.

    Time frame: From baseline (week 0) to week 84

Secondary outcomes

  1. Change in waist circumference

    Measured as centimetre (cm).

    Time frame: From baseline (week 0) to week 84 and week 136

  2. Change in systolic blood pressure (SBP)

    Measured as millimetre of mercury (mmHg).

    Time frame: From baseline (week 0) to week 84 and week 136

  3. Change in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) physical function score

    Measured as score on a scale. IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Higher scores indicate better levels of functioning. The physical function score ranges from 0-100.

    Time frame: From baseline (week 0) to week 84 and week 136

  4. Change in SF-36v2® Health Survey Acute (SF-36v2 Acute) physical functioning score

    Measured as score on a scale. SF-36v2 Acute measures Health-Related Quality of Life (HRQOL). The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 Acute scores are norm-based scores, i.e. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation (SD) of 10. Higher scores indicate better functional health and well-being. The physical functioning ranges from 19.0 to 57.6.

    Time frame: From baseline (week 0) to week 84 and week 136

  5. Change in body weight

    Measured as kilogram (kg).

    Time frame: From baseline (week 0) to week 84 and week 136

  6. Change in body mass index (BMI)

    Measured as kilograms per meter squared (kg/m\^2).

    Time frame: From baseline (week 0) to week 84 and week 136

  7. Change in IWQOL-Lite-CT physical composite score

    Measured as score on a scale. IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Higher scores indicate better levels of functioning. The physical composite score ranges from 0-100.

    Time frame: From baseline (week 0) to week 84 and week 136

  8. Change in IWQOL-Lite-CT psychosocial composite score

    Measured as score on a scale. IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Higher scores indicate better levels of functioning. The psychosocial composite score ranges from 0-100.

    Time frame: From baseline (week 0) to week 84 and week 136

  9. Change in IWQOL-Lite-CT total score

    Measured as score on a scale. IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Higher scores indicate better levels of functioning. The total score ranges from 0-100.

    Time frame: From baseline (week 0) to week 84 and week 136

  10. Change in glycated haemoglobin (HbA1c)

    Measured as percentage of HbA1c.

    Time frame: From baseline (week 0) to week 84 and week 136

  11. Change in fasting plasma glucose (FPG)

    Measured as millimole per liter (mmol/L).

    Time frame: From baseline (week 0) to week 84 and week 136

  12. Ratio to baseline: change in fasting insulin

    Measured as ratio.

    Time frame: From baseline (week 0) to week 84 and week 136

  13. Change in diastolic blood pressure (DBP)

    Measured as mmHg.

    Time frame: From baseline (week 0) to week 84

  14. Ratio to baseline: change in total cholesterol

    Measured as ratio.

    Time frame: From baseline (week 0) to week 84 and week 136

  15. Ratio to baseline: change in high-density lipoprotein (HDL) cholesterol

    Measured as ratio.

    Time frame: From baseline (week 0) to week 84 and week 136

  16. Ratio to baseline: change in low-density lipoprotein (LDL) cholesterol

    Measured as ratio.

    Time frame: From baseline (week 0) to week 84 and week 136

  17. Ratio to baseline: change in very low-density lipoprotein (VLDL) cholesterol

    Measured as ratio.

    Time frame: From baseline (week 0) to week 84 and week 136

  18. Ratio to baseline: change in non-HDL cholesterol

    Measured as ratio.

    Time frame: From baseline (week 0) to week 84 and week 136

  19. Ratio to baseline: change in triglycerides

    Measured as ratio.

    Time frame: From baseline (week 0) to week 84 and week 136

  20. Ratio to baseline: change in high-sensitivity C-reactive protein (hsCRP)

    Measured as ratio.

    Time frame: From baseline (week 0) to week 84 and week 136

  21. Number of treatment emergent adverse events (TEAEs)

    Measured as events.

    Time frame: From baseline (week 0) to week 84 and week 140

  22. Number of treatment emergent serious adverse events (TESAEs)

    Measured as events.

    Time frame: From baseline (week 0) to week 84 and week 140

  23. Number of TEAEs leading to permanent treatment discontinuation

    Measured as events.

    Time frame: From baseline (week 0) to week 84 and week 140

  24. Relative change in body weight

    Measured as % of body weight.

    Time frame: From baseline (week 0) to week 136

07

Study locations

65 of 72 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Jun 2029, 40 months after the start.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 40 months is above that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2026
First posted
Jan 14, 2026
StartActual
Feb 24, 2026
Primary completionEst.
Jun 26, 2029
CompletionEst.
Aug 21, 2029
Last update
Sep 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07339423
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jan 14, 2026
Start date
Feb 24, 2026
Primary completion
Jun 26, 2029 (estimated)
Completion
Aug 21, 2029 (estimated)
Last update
Sep 24, 2026

Study contacts

Novo Nordisk
Contact
clinicaltrials@novonordisk.com
(+1) 866-867-7178
Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zenagamtide

Start the discussion